SabrinaPaganoniMD

Physical Medicine/Rehab • Charlestown, MA

Neuromuscular Medicine

Associate Professor PM&R, Harvard Medical School, Spaulding Rehabilitation Hospital, Massachusetts General Hospital

Join to view full profile

Dr. Paganoni is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Paganoni's full profile

Already have an account?

Office
300 1st Ave
# Spauldin
Charlestown, MA 02129
Phone+1 617-952-5000

Education & Training

Spaulding Rehabilitation Hospital/Harvard Medical SchoolResidency, Physical Medicine and Rehabilitation, 2008 - 2011
Louis A Weiss Memorial HospitalInternship, Internal Medicine, 2007 - 2008
University of Milan Faculty of MedicineClass of 1999

Certifications & Licensure

MA State Medical License 2011 - 2026
ME State Medical License 2021 - 2026
NH State Medical License 2021 - 2025
RI State Medical License 2021 - 2022
American Board of Physical Medicine and Rehabilitation Physical Medicine & Rehabilitation
American Board of Physical Medicine and Rehabilitation Neuromuscular Medicine

Clinical Trials

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Start of enrollment: 2015 Jun 01
Completed
Phase 2
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2017 Jun 22
Completed
Phase 2

Publications & Presentations

PubMed

1 citations
Access for ALL in ALS: A large-scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosis.
James D Berry, Sabrina Paganoni, Matthew B Harms, Neil Shneider, Jinsy Andrews
Muscle & Nerve. 2024-12-01
Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis.
Sabrina Paganoni, Brittney Harkey, Elisa Giacomelli, Merit Cudkowicz,
Nature Aging. 2024-11-01
Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis.
Elisabetta Pupillo, Elisa Bianchi, Valentina Bonetto, Laura Pasetto, Caterina Bendotti
Brain, Behavior, and Immunity. 2024-11-01

Journal Articles

Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Sabrina Paganoni, Michael A Elliott, Samuel Maiser, Margaret A Owegi, Stephen A Goutman, Carlayne E Jackson, Jeffrey D Rothstein, Edward J Kasarskis, Liberty Jenkins, ..., The New England Journal of Medicine
Integrated Imaging of [11C]-PBR28 PET, MR Diffusion and Magnetic Resonance Spectroscopy 1H-MRS in Amyotrophic Lateral Sclerosis
Sabrina Paganoni, Nazem Atassi, Suma Babu, ScienceDirect

Press Mentions

How the Healy ALS Platform Trial Is Helping to Accelerate the Pathway to New ALS TreatmentsDecember 5th, 2024
MDA Awards $500,000 Grant to Accelerate ALS Research Through the HEALEY ALS Platform Trial at Massachusetts General HospitalSeptember 19th, 2024
AAN 2023: ALS Treatments ID’d in HEALEY Head Toward Phase 3 TestsApril 27th, 2023
Join now to see all

Professional Memberships

American Academy of Physical Medicine and Rehabilitation - AAPMR
Member